Cover image of the article: Challenge in cancer therapy with VAP- 1 inhibition strategy: possible interference of this type of intervention within protection from autoimmunity: Hypothesis

Image Credit:J Rep Pharm Sci

Challenge in cancer therapy with VAP- 1 inhibition strategy: possible interference of this type of intervention within protection from autoimmunity: Hypothesis

Authors

Mohammad Erfan Zare1, 2,*, Reza Khodarahmi1,**, Seyyed Abolghasem Ghadami1, Atefeh Nasir Kansestani1, 2

Abstract

Vascular adhesion protein-1 (VAP-1) is an endothelial cell surface-expressed oxidase involved in leukocyte traffic. The adhesive function, and therefore leukocyte infiltration to different tissues, can be blocked by anti-VAP-1 antibodies as well as small molecule VAP-1 inhibitors. Several papers have been published on the effect of VAP-1 blockade on both leukocyte accumulation into tumors and neoangiogenesis. Additionally, myeloid derived suppressor cells (MDSCs) have been identified as immunosuppressive cells associated with tumor expansion. Moreover, some of them (such as CD11b+ myeloid cells) appear to be intrinsically suppressive and may have a key role in maintaining immune homeostasis and protection from autoimmunity. Since VAP-1 supports leukocyte emigration (including MDSCs) to normal tissues and sites of inflammation like tumor tissue, its inhibition has been suggested as potential cancer immunotherapy intervention. Moreover, since these types of suppressive cells use VAP-1 mediated strategy for their adhe- sion and infiltration, it is hypothesized that VAP-1 inhibition may lead to partial loss of suppressive function on immune system and therefore induce the development of autoimmune diseases like relapsing-remitting (experimental) autoimmune encephalomyelitis. 

Highlights

How to Cite:Zare ME, Khodarahmi R, Ghadami SA, Nasir Kansestani A. Challenge in cancer therapy with VAP- 1 inhibition strategy: possible interference of this type of intervention within protection from autoimmunity: Hypothesis. J Rep Pharm Sci. 2012;1(2):e147773. doi:

Copyright

© 2012, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.

Similar Articles

19
Jan
2023
Tumor Suppression by PD-1/PD-L1 Interaction Blockage in Mice Model

Tumor Suppression by PD-1/PD-L1 Interaction Blockage in Mice Model

Shima Salehi,
Hajarossadat Ghaderi,
Mahdi Habibi-Anbouhi,
Alireza Shoari,
Ayda Hassanzadeh Eskafi,
Alireza Sabouri
,et al.

Salehi S, Ghaderi H, Habibi-Anbouhi M, Shoari A, Hassanzadeh Eskafi A, et al. Tumor Suppression by PD-1/PD-L1 Interaction Blockage in Mice Model. Iran J Pharm Res. 2022;21(1):e132329. doi: https://doi.org/10.5812/ijpr-132329

28
Oct
2012
Serum Lipid Profile in Psoriatic Patients in Kermanshah: A Survey on Vascular Adhesion Protein-1

Serum Lipid Profile in Psoriatic Patients in Kermanshah: A Survey on Vascular Adhesion Protein-1

Houshang Nemati,
Reza Khodarahmi,
Masoud Sadeghi,
Ameneh Rahmani,
Mansour Rezaei

Nemati H, Khodarahmi R, Sadeghi M, Rahmani A, Rezaei M. Serum Lipid Profile in Psoriatic Patients in Kermanshah: A Survey on Vascular Adhesion Protein-1. Zahedan J Res Med Sci. 2013;15(2):e93082. doi:

12
Aug
2025
Expression Modulation of Immune Inhibitory Molecules by Small Molecule Inhibitor Drugs in Leukemic Cells of Chronic Lymphocytic Leukemia

Expression Modulation of Immune Inhibitory Molecules by Small Molecule Inhibitor Drugs in Leukemic Cells of Chronic Lymphocytic Leukemia

Fatemeh Mousavi-Mirkalaei,
Saeid Taghiloo,
Maryam Alizadeh-Foroutan,
Ehsan Zaboli,
Mohammad Eslami-Jouybari,
Ramin Shekarriz
,et al.

Mousavi-Mirkalaei F, Taghiloo S, Alizadeh-Foroutan M, Zaboli E, Eslami-Jouybari M, et al. Expression Modulation of Immune Inhibitory Molecules by Small Molecule Inhibitor Drugs in Leukemic Cells of Chronic Lymphocytic Leukemia. Iran J Pharm Res. 2025;24(1):e159353. doi: https://doi.org/10.5812/ijpr-159353

30
Sep
2026
Targeting PD-1/PD-L1 in Advanced Thyroid Cancer: Therapeutic Efficacy, Predictive Biomarkers, and Clinical Challenges (AI-generated illustration)

Targeting PD-1/PD-L1 in Advanced Thyroid Cancer: Therapeutic Efficacy, Predictive Biomarkers, and Clinical Challenges

Maziar Motiee-Langroudi,
Ebrahim Karimi,
Saeed Sohrabpour,
Keyvan Aghazadeh,
Farrokh Heidari,
Mohammad Rasoul Ghadami

Motiee-Langroudi M, Karimi E, Sohrabpour S, Aghazadeh K, Heidari F, et al. Targeting PD-1/PD-L1 in Advanced Thyroid Cancer: Therapeutic Efficacy, Predictive Biomarkers, and Clinical Challenges. J Kermanshah Univ Med Sci. 2026;In Press(In Press):e176099. doi: https://doi.org/10.5812/jkums-176099

31
Jul
2026
Dengue Virus NS1 Protein and Vascular Leakage: Current Concepts, Mechanistic Insights, and Future Perspectives

Dengue Virus NS1 Protein and Vascular Leakage: Current Concepts, Mechanistic Insights, and Future Perspectives

Arya Abdollahi,
Ebrahim Kord,
Iliad Moradi,
Abdolvahab Moradi

Abdollahi A, Kord E, Moradi I, Moradi A. Dengue Virus NS1 Protein and Vascular Leakage: Current Concepts, Mechanistic Insights, and Future Perspectives. Int J Infect. 2026;13(2):e175458. doi: https://doi.org/10.5812/iji-175458

More by these authors

Mohammad Erfan ZarePubMedScholar
Reza KhodarahmiPubMedScholar
Seyyed Abolghasem GhadamiPubMedScholar
Atefeh Nasir KansestaniPubMedScholar
Share
Cited by
Metrics
Indexed in